1 f morphine by administering naloxone with an alpha2 antagonist.

2 oventricular (i.c.v.) infusion of vehicle or alpha2-antagonist.

3 agonist, but was unaffected by yohimbine, an alpha2-antagonist.

4 1 antagonist, 4 mg/kg), but not idazoxan (an alpha2 antagonist, 1 mg/kg), administered intravenously

5                              In search of an alpha2-antagonist/5-HT uptake inhibitor as a potential n

6 nimodipine was blocked by either a selective alpha2 antagonist, a cyclic adenosine monophosphate (cAM

7 ect LC cholinergic stimulation combined with alpha2 antagonists and alpha1 agonists in a mixture to r

8  The response could be blocked by a specific alpha2-antagonist and a muscarinic antagonist.

9  conclusion, administration of the selective alpha2-antagonist atipamezole to rats chronically treate

10 ressive action of brimonidine was blocked by alpha2 antagonists, cAMP analogs, an adenylate cyclase a

11 ine (CLON; 1.32 nmol), and half received the alpha2 antagonist idazoxan (IDA; 0.33 nmol).

12                                          The alpha2 antagonist idazoxan and the beta antagonist propr

13                                          The alpha2 antagonist idazoxan increased spike frequency, su

14 a-antagonist phentolamine (10 microM) or the alpha2-antagonist idazoxan (2 microM).

15 e neuroprotective effect was abolished by an alpha2 antagonist or a PDE4 inhibitor in both in vivo mo

16 ns of adrenaline were prevented by alpha1 or alpha2 antagonists, respectively.

17 uency after hypoxia was not prevented by the alpha2-antagonists, RX 821002 or SK&F-86466.

18                                    While the alpha2-antagonists, yohimbine, rauwolscine and idazoxan